Spironolactone use is associated with lower prostate cancer risk a populationwide casecontrol study

Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study

19:24 EST 2 Mar 2020 | Nature Publishing

More From BioPortfolio on "Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study"